| Primary |
|
| Respiratory Failure |
100.0% |
|
| Secondary |
| Pneumonia |
16.4% |
| Product Used For Unknown Indication |
12.3% |
| Abdominal Infection |
11.6% |
| Tuberculosis Of Central Nervous System |
9.7% |
| Antibiotic Therapy |
6.3% |
| Acinetobacter Infection |
6.0% |
| Klebsiella Infection |
5.6% |
| Pseudomonas Infection |
5.2% |
| Postoperative Wound Infection |
4.5% |
| Lower Respiratory Tract Infection |
3.0% |
| Sepsis |
3.0% |
| Bacterial Infection |
2.2% |
| Endotracheal Intubation |
2.2% |
| Immunosuppression |
2.2% |
| Stenotrophomonas Infection |
2.2% |
| Acute Myeloid Leukaemia |
1.5% |
| Cardiac Disorder |
1.5% |
| Cns Ventriculitis |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Pneumonia Bacterial |
1.5% |
|
| Death |
10.0% |
| Pathogen Resistance |
10.0% |
| Renal Failure Acute |
10.0% |
| Neutropenia |
7.5% |
| Cardiac Arrest |
5.0% |
| Colitis |
5.0% |
| Neuropathy Peripheral |
5.0% |
| Ototoxicity |
5.0% |
| Pneumonia Bacterial |
5.0% |
| Rash |
5.0% |
| Sepsis |
5.0% |
| Stenotrophomonas Infection |
5.0% |
| Trichosporon Infection |
5.0% |
| Bronchopulmonary Aspergillosis |
2.5% |
| Drug Ineffective |
2.5% |
| Erythema Multiforme |
2.5% |
| Hepatic Failure |
2.5% |
| Klebsiella Test Positive |
2.5% |
| Maternal Exposure During Pregnancy |
2.5% |
| Nephropathy Toxic |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.2% |
| Drug Use For Unknown Indication |
19.3% |
| Prophylaxis |
6.9% |
| Acute Myeloid Leukaemia |
5.9% |
| Acinetobacter Infection |
4.0% |
| Peritonitis |
3.8% |
| Pneumonia |
3.8% |
| Post Procedural Infection |
3.8% |
| Cystic Fibrosis |
3.4% |
| Bronchopulmonary Aspergillosis |
2.9% |
| Pseudomonas Infection |
2.5% |
| Prophylaxis Against Transplant Rejection |
2.0% |
| Catheter Related Infection |
1.9% |
| Infection |
1.9% |
| Septic Shock |
1.9% |
| Aspergillosis |
1.6% |
| Trichosporon Infection |
1.4% |
| Respiratory Tract Infection |
1.3% |
| Staphylococcal Infection |
1.3% |
| Immunosuppressant Drug Therapy |
1.2% |
|
| Sepsis |
13.2% |
| Treatment Failure |
12.3% |
| Septic Shock |
11.3% |
| Respiratory Failure |
6.6% |
| Death |
4.7% |
| Drug Interaction |
4.7% |
| Renal Failure Acute |
4.7% |
| Vomiting |
4.7% |
| Fungaemia |
3.8% |
| Hepatotoxicity |
3.8% |
| Pulmonary Oedema |
3.8% |
| Renal Impairment |
3.8% |
| Cytomegalovirus Infection |
2.8% |
| Fungal Endocarditis |
2.8% |
| International Normalised Ratio Increased |
2.8% |
| Pneumonia |
2.8% |
| Pyrexia |
2.8% |
| Rash |
2.8% |
| Shock |
2.8% |
| Staphylococcal Infection |
2.8% |
|
| Interacting |
| Pseudomonas Infection |
50.0% |
| Antiinflammatory Therapy |
25.0% |
| Arthropathy |
25.0% |
|
|
